HC Wainwright Reaffirms Buy Rating for Alpha Cognition (NASDAQ:ACOG)

Alpha Cognition (NASDAQ:ACOGGet Free Report)‘s stock had its “buy” rating reiterated by HC Wainwright in a note issued to investors on Monday,Benzinga reports. They currently have a $20.00 price objective on the stock. HC Wainwright’s target price indicates a potential upside of 312.37% from the company’s previous close.

Separately, Raymond James raised shares of Alpha Cognition to a “moderate buy” rating in a research note on Tuesday, March 25th.

Check Out Our Latest Research Report on Alpha Cognition

Alpha Cognition Trading Down 4.2 %

Shares of NASDAQ:ACOG opened at $4.85 on Monday. The firm has a market cap of $77.70 million, a PE ratio of -1.89 and a beta of 2.50. Alpha Cognition has a one year low of $4.66 and a one year high of $7.00. The company’s fifty day moving average is $5.81.

Alpha Cognition (NASDAQ:ACOGGet Free Report) last released its quarterly earnings results on Monday, March 31st. The company reported ($0.51) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.03).

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. Solas Capital Management LLC acquired a new position in Alpha Cognition during the fourth quarter worth about $8,096,000. Sphera Funds Management LTD. bought a new position in shares of Alpha Cognition during the 4th quarter valued at $3,652,000. Alyeska Investment Group L.P. acquired a new stake in shares of Alpha Cognition in the fourth quarter worth about $2,356,000. Altium Capital Management LLC bought a new stake in shares of Alpha Cognition during the 4th quarter worth $1,620,000. Finally, Rosalind Advisors Inc. acquired a new stake in Alpha Cognition in the 4th quarter valued at approximately $1,489,000.

About Alpha Cognition

(Get Free Report)

Alpha Cognition, Inc is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer’s Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.

Read More

Receive News & Ratings for Alpha Cognition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpha Cognition and related companies with MarketBeat.com's FREE daily email newsletter.